

**Table 4**

2,8-Dihydroxyadenine-to-creatinine ratio in first morning void urine samples at baseline and at the completion of allopurinol and febuxostat treatment periods.

Patient	Baseline	Allopurinol	Febuxostat
	DHA/Cr (mg/mmol)	DHA/Cr (mg/mmol)	DHA/Cr (mg/mmol)
1	12.5	4.4	0.9 <sup>a</sup>
2	22.8	7.0	ND
3	34.5	5.4	1.1 <sup>a</sup>
4	8.2	2.8	0.8 <sup>a</sup>
5	17.4	8.4	1.1 <sup>a</sup>
6	13.9	5.6	ND
7	15.2	1.1 <sup>a</sup>	ND
8	16.9	5.1	ND

Abbreviations: Cr, creatinine; DHA, 2,8-dihydroxyadenine.

ND, not detectable (limit of detection < 20 ng/mL).

<sup>a</sup> Below limit of quantification (< 100 ng/mL).